Citation Impact
Citing Papers
Assessing the incremental value of diagnostic and prognostic markers: a review and illustration
2011
Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): The TRIPOD statement
2015 Standout
Hallmarks of Cancer: The Next Generation
2011 Standout
Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement
2015 Standout
Testicular Germ-Cell Cancer
1997 Standout
Towards better clinical prediction models: seven steps for development and an ABCD for validation
2014 Standout
Transmission of donor melanoma by organ transplantation
2010
Clinical relevance of the molecular mechanisms of resistance to anti-cancer drugs
1999
A Predictive Model for Progression of Chronic Kidney Disease to Kidney Failure
2011 Standout
Cancer Stem Cells: Impact, Heterogeneity, and Uncertainty
2012 Standout
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicity.
1996
Role of biochemical markers in testicular cancer: diagnosis, staging, and surveillance
2011
Internal validation of predictive models
2001 Standout
The resurgence of platinum-based cancer chemotherapy
2007 Standout
Nanoparticles in cancer therapy and diagnosis
2002 Standout
Postchemotherapy residual masses in germ cell tumor patients
1998
Molecular mechanisms of cisplatin resistance
2011 Standout
Second Cancers Among 40 576 Testicular Cancer Patients: Focus on Long-term Survivors
2005 Standout
Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers
2010 Standout
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
2010 Standout
The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population
2006 Standout
Calculating the sample size required for developing a clinical prediction model
2020 Standout
Assessing the Performance of Prediction Models
2009 Standout
A systematic review shows no performance benefit of machine learning over logistic regression for clinical prediction models
2019 Standout
Medical Treatment of Advanced Testicular Cancer
2008
Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD Statement
2015 Standout
Predicting Mortality Among Patients Hospitalized for Heart Failure
2003 Standout
Substantial effective sample sizes were required for external validation studies of predictive logistic regression models
2005
Metastatic colonization by circulating tumour cells
2016 StandoutNature
What You See May Not Be What You Get: A Brief, Nontechnical Introduction to Overfitting in Regression-Type Models
2004 Standout
Radiomics: the bridge between medical imaging and personalized medicine
2017 Standout
Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma.
1997
Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients.
1996
Phase 2 trial of the cyclin‐dependent kinase 4/6 inhibitor palbociclib in patients with retinoblastoma protein‐expressing germ cell tumors
2014
Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration
2015 Standout
Childhood and adolescent cancer statistics, 2014
2014 Standout
Residual mass histology in testicular cancer: development and validation of a clinical prediction rule
2001
Prognostic Modeling with Logistic Regression Analysis
2001
Curing metastatic testicular cancer
2002
VALIDATION OF A PREDICTION MODEL AND ITS PREDICTORS FOR THE HISTOLOGY OF RESIDUAL MASSES IN NONSEMINOMATOUS TESTICULAR CANCER
2001
Long-Term Medical Care of Testicular Cancer Survivors
2002
Extending the c‐statistic to nominal polytomous outcomes: the Polytomous Discrimination Index
2012
Resection of small, residual retroperitoneal masses after chemotherapy for nonseminomatous testicular cancer
1999
Postchemotherapy Retroperitoneal Surgery Remains Necessary in Patients With Nonseminomatous Testicular Cancer and Minimal Residual Tumor Masses
2003
Resection of small, residual retroperitoneal masses after chemotherapy for nonseminomatous testicular cancer: a decision analysis.
1999
Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): The TRIPOD Statement
2015 Standout
Regression Modeling Strategies
2015 Standout
Works of Jonathan E. Messemer being referenced
Surgical salvage of chemorefractory germ cell tumors.
1993
Late relapse of testicular cancer.
1995
Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups.
1995
The Management of Patients with Clinical Stage I Nonseminomatous Testicular Tumors and Persistently Elevated Serologic Markers
1996
Residual pulmonary masses after chemotherapy for metastatic nonseminomatous germ cell tumor
1997
Residual pulmonary masses after chemotherapy for metastatic nonseminomatous germ cell tumor. Prediction of histology. ReHiT Study Group.
1997